 |
| |
| Jun-05-19 | Upgrade |
Standpoint Research |
Hold → Buy |
|
|
| May-23-19 | Resumed |
Citigroup |
Neutral |
|
|
| May-23-19 | Initiated |
Wedbush |
Neutral |
|
|
| May-21-19 | Initiated |
Credit Suisse |
Underperform |
$198 |
|
| Apr-10-19 | Resumed |
Raymond James |
Mkt Perform |
|
|
| Mar-25-19 | Reiterated |
H.C. Wainwright |
Buy |
$363 → $300 |
|
| Mar-22-19 | Reiterated |
BMO Capital Markets |
Market Perform |
$322 → $250 |
|
| Mar-22-19 | Downgrade |
UBS |
Buy → Neutral |
$395 → $242 |
|
| Mar-22-19 | Downgrade |
Morgan Stanley |
Overweight → Underweight |
$401 → $210 |
|
| Mar-22-19 | Downgrade |
Canaccord Genuity |
Buy → Hold |
$396 → $275 |
|
| Mar-21-19 | Reiterated |
Guggenheim |
Neutral |
$325 |
|
| Mar-21-19 | Downgrade |
William Blair |
Outperform → Mkt Perform |
|
|
| Mar-21-19 | Downgrade |
Wells Fargo |
Outperform → Market Perform |
|
|
| Mar-21-19 | Downgrade |
Mizuho |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Mar-21-19 | Downgrade |
Goldman |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
Citigroup |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
BofA/Merrill |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
Atlantic Equities |
Overweight → Neutral |
|
|
| Feb-21-19 | Downgrade |
Stifel |
Buy → Hold |
$397 → $346 |
|
|
|
| Jun-18-19 08:00AM | 3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal Motley Fool |
| 07:09AM | Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch |
| Jun-17-19 09:51AM | AstraZeneca Gives Detailed Data From Calquence Leukemia Study Zacks |
| Jun-14-19 12:03PM | Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures Investor's Business Daily |
| Jun-13-19 05:50PM | Biogen (BIIB) Gains But Lags Market: What You Should Know Zacks |
| 04:12PM | Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch |
| 06:00AM | Ontario grants broader access to SPINRAZA (nusinersen) for patients living with spinal muscular atrophy (SMA) CNW Group |
| Jun-12-19 12:49PM | Biogen Inc. (NASDAQ:BIIB) Insiders Increased Their Holdings Simply Wall St. |
| 09:27AM | Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks |
| Jun-11-19 07:05PM | Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019 GlobeNewswire |
| 11:26AM | Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder InvestorPlace |
| Jun-10-19 04:40PM | Is Biogen Inc. (BIIB) A Good Stock To Buy? Insider Monkey |
| Jun-07-19 05:50PM | Biogen (BIIB) Outpaces Stock Market Gains: What You Should Know Zacks |
| 05:00PM | Celgene's Filing for Ozanimod Accepted for Review in US/EU Zacks |
| 05:41AM | Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million GlobeNewswire |
| Jun-06-19 04:19PM | Will This Downbeat Biotech Regain Investor Trust With ALS Drugs? Investor's Business Daily |
| 10:38AM | Biogen Stock Is Slipping Because Investors Dont Buy Its News on Lou Gehrigs Disease Barrons.com |
| May-31-19 09:07AM | Biogen Reports Interim Phase III Data on Diroximel Fumarate Zacks |
| 08:11AM | Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs Zacks |
| May-30-19 11:02AM | PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts Zacks |
| 07:30AM | New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis GlobeNewswire |
| 07:15AM | The Case for a Biogen Acquisition and 3 Potential Targets Barrons.com |
| May-29-19 05:50PM | Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Zacks |
| 08:59AM | Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma Zacks |
| May-28-19 07:00AM | Primecaps Golden Lineup: Its Six Funds Come in Pairs Morningstar |
| May-27-19 11:10AM | Novartis Gene Therapy Crosses The $2 Million Mark Will Others Follow? Investor's Business Daily |
| 06:48AM | Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems Zacks |
| May-24-19 07:39PM | Novartis $2 million gene therapy for rare disorder is world's most expensive drug Reuters |
| 07:39PM | For Anderson family, an early bet on SMA gene therapy Reuters |
| 01:30PM | Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval American City Business Journals |
| 10:55AM | Biogen Stock One of the Best to Own Next Week Schaeffer's Investment Research |
| 09:31AM | Biogen (BIIB) Down 0.3% Since Last Earnings Report: Can It Rebound? Zacks |
| May-23-19 05:27PM | Preclinical biotech Stoke Therapeutics plans $86M IPO American City Business Journals |
| 03:53PM | Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY) Zacks |
| 11:44AM | The Patient View: Biogen Alzheimer's Trial Participant Jeff Borghoff at Healthy Returns CNBC Videos |
| 09:17AM | The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific Zacks |
| 09:06AM | Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE PR Newswire |
| 07:10AM | The top-performing hedge funds are buying GE, Facebook, Biogen and these other stocks CNBC |
| May-22-19 04:30PM | 3 Tech Stocks for Growth Investors to Buy Right Now Zacks |
| 02:43PM | Top Research Reports for Chubb, Las Vegas Sands & Biogen Zacks |
| 11:34AM | Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN Zacks |
| 05:35AM | The Best and Worst Big Biotech Stocks, According to One Analyst Barrons.com |
| May-21-19 04:55PM | We don't yet have the technology to cure Alzheimer's, health-care investor says CNBC |
| 03:00PM | Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending Insider Monkey |
| May-20-19 04:30PM | Biogen Urges Shareholders To Reject Low-Ball Mini-Tender Offer Investor's Business Daily |
| 07:40AM | Biogen urges shareholders to reject 'below-market' mini-tender offer from TRC Capital MarketWatch |
| 07:30AM | Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation GlobeNewswire |
| May-17-19 05:17PM | Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid Zacks |
| May-16-19 02:54PM | Wayfair cracks Fortune 500 list, joins 15 other Mass. companies American City Business Journals |
| 05:00AM | Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks Barrons.com |
| May-15-19 07:50AM | Stocks making the biggest moves premarket: Alibaba, Zillow Group, Biogen, McDonald's, Beyond Meat & more CNBC |
| 07:50AM | The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi Benzinga |
| 07:42AM | 5 Low Price-to-Book Value Stocks for Great Returns Zacks |
| May-14-19 08:05PM | NHS England, Biogen reach deal on pricey drug for deadly disorder Reuters |
| 07:07PM | NHS England, Biogen reach deal on pricey drug for deadly disorder Reuters |
| 07:02PM | Biogens SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy GlobeNewswire |
| 03:51PM | Ionis Pharmaceuticals Is 40% of the Way There Motley Fool |
| May-13-19 04:24PM | Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store? Zacks |
| 08:00AM | Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease PR Newswire |
| May-10-19 10:51AM | PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y Zacks |
| 08:40AM | Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease PR Newswire |
| May-09-19 12:32PM | Stock Buybacks Surge Kiplinger |
| May-08-19 04:49PM | Parnassus Endeavor Fund Buys AbbVie, Boosts Biogen GuruFocus.com |
| 01:44PM | Jeff Auxier Comments on Biogen GuruFocus.com |
| 01:18PM | Jeff Auxier's 1st Quarter Auxier Focus Fund Shareholder Letter GuruFocus.com |
| May-07-19 04:57PM | Biotech ETFs in Focus on String of Q1 Earnings Beats Zacks |
| 04:33PM | This Biotech Has A 'Swing Factor' In SMA Drugs And It's Slugging Biogen Investor's Business Daily |
| 07:30AM | Data at AAN Demonstrate Biogens Leadership and Commitment to Innovation in MS GlobeNewswire |
| May-06-19 04:53PM | Jerome Dodson Comments on Biogen GuruFocus.com |
| 11:20AM | Weekly CEO Buys Highlight GuruFocus.com |
| 07:44AM | Notable Insider Buys This Past Week: ADM, Biogen, Grubhub and More Benzinga |
| 07:30AM | Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen) GlobeNewswire |
| 07:00AM | Biogen Stock Is Near a Multiyear Low. The CEO and a Hedge Fund Bought Millions. Barrons.com |
| May-05-19 03:27PM | Top Insider Buys Highlight for the Week of May 3 GuruFocus.com |
| May-02-19 01:21PM | These 6 biotech stocks are promising takeover targets MarketWatch |
| 11:18AM | The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex Zacks |
| 11:05AM | Betting Against Biogen Stock Might Be Fashionable, but Its a Mistake, Analyst Says Barrons.com |
| 10:24AM | What Do Analysts Think About Biogen Inc.'s (NASDAQ:BIIB) Future? Simply Wall St. |
| 08:16AM | The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data Benzinga |
| May-01-19 04:30PM | Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) GlobeNewswire |
| 01:36PM | David Carlson Buys 2 Stocks, Sells 1 in 1st Quarter GuruFocus.com |
| 11:52AM | Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates Zacks |
| 09:26AM | What's in the Cards for Sunesis (SNSS) This Earnings Season? Zacks |
| 07:30AM | Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases GlobeNewswire |
| Apr-30-19 12:46PM | 3 Tech Stocks for Growth Investors to Buy Right Now Zacks |
| 11:44AM | Biogen Is 3 Adding Directors. Investors Might Question Whether Thats Bold Enough. Barrons.com |
| 10:54AM | 10 Workhorse Health Care Stocks That Never Break a Sweat Kiplinger |
| 10:53AM | The 10 Best Health Care Stocks to Buy for 2019 Kiplinger |
| 07:33AM | Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy GlobeNewswire |
| Apr-29-19 07:30AM | Biogen Announces Three New Nominees for Election to Board of Directors GlobeNewswire |
| Apr-28-19 11:19AM | Biogen says it will not give up on Alzheimers after failed trials MarketWatch |
| Apr-27-19 11:54AM | Cramer's Takeaways for Ford, Chevron, Alibaba, Biogen, Visa TheStreet.com |
| Apr-26-19 04:21PM | Is This Highly-Anticipated Gene Therapy in Trouble? Motley Fool |
| 03:58PM | Alkermes Looks Ahead to Growth Motley Fool |
| 07:26AM | Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1 Zacks |
| 06:10AM | Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals |
| Apr-25-19 04:37PM | Jerome Dodson's 1st Quarter Parnassus Endeavor Fund Commentary GuruFocus.com |
| 03:47PM | Biogen Looks to 23 Clinical Programs for Growth Motley Fool |
| 03:10PM | Bitcoin and Biogen among the second round 2019 Stock Draft picks CNBC Videos |
| 02:46PM | Here is who's competing in the 2019 Stock Draft, the rules and the first pick CNBC Videos |
|
|
|
|
| Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Ehlers Michael D | EVP, Research and Development | Jun 01 | Option Exercise | 0.00 | 1,126 | 0 | 8,525 | Jun 04 04:56 PM | | Vounatsos Michel | Chief Executive Officer | May 02 | Option Exercise | 0.00 | 1,480 | 0 | 22,487 | May 06 04:20 PM | | DENNER ALEXANDER J | Director | May 02 | Buy | 231.24 | 38,000 | 8,787,120 | 643,000 | May 02 05:06 PM | | Vounatsos Michel | Chief Executive Officer | May 01 | Buy | 231.48 | 4,351 | 1,007,169 | 21,007 | May 02 04:30 PM | | DENNER ALEXANDER J | Director | May 01 | Buy | 229.46 | 30,000 | 6,883,800 | 605,000 | May 02 05:06 PM | | DENNER ALEXANDER J | Director | Apr 30 | Buy | 229.25 | 50,342 | 11,540,904 | 575,000 | May 02 05:06 PM | | PANGIA ROBERT W | Director | Mar 18 | Option Exercise | 52.22 | 6,114 | 319,273 | 24,701 | Mar 19 04:08 PM | | PANGIA ROBERT W | Director | Mar 18 | Sale | 328.55 | 6,114 | 2,008,755 | 18,587 | Mar 19 04:08 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Mar 01 | Option Exercise | 0.00 | 568 | 0 | 7,488 | Mar 05 04:17 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 22 | Option Exercise | 38.51 | 8,058 | 310,285 | 36,085 | Feb 26 05:09 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 22 | Option Exercise | 0.00 | 1,663 | 0 | 11,148 | Feb 26 05:07 PM | | Vounatsos Michel | Chief Executive Officer | Feb 15 | Option Exercise | 0.00 | 5,269 | 0 | 18,914 | Feb 20 06:10 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 15 | Option Exercise | 0.00 | 1,318 | 0 | 10,071 | Feb 20 06:08 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Feb 15 | Option Exercise | 0.00 | 1,448 | 0 | 7,968 | Feb 20 06:07 PM | | Ehlers Michael D | EVP, Research and Development | Feb 15 | Option Exercise | 0.00 | 1,685 | 0 | 8,526 | Feb 20 05:54 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 15 | Option Exercise | 0.00 | 1,685 | 0 | 28,776 | Feb 20 05:53 PM | | Vounatsos Michel | Chief Executive Officer | Feb 12 | Option Exercise | 0.00 | 6,899 | 0 | 16,267 | Feb 14 06:33 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 12 | Option Exercise | 0.00 | 4,643 | 0 | 9,452 | Feb 14 06:29 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Feb 12 | Option Exercise | 0.00 | 3,062 | 0 | 7,059 | Feb 14 06:17 PM | | Gregory Ginger | EVP, Human Resources | Feb 12 | Option Exercise | 0.00 | 1,836 | 0 | 2,561 | Feb 14 06:10 PM | | Ehlers Michael D | EVP, Research and Development | Feb 12 | Option Exercise | 0.00 | 3,827 | 0 | 7,639 | Feb 14 06:07 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 12 | Option Exercise | 0.00 | 3,268 | 0 | 27,710 | Feb 14 06:04 PM | | DENNER ALEXANDER J | Director | Feb 01 | Buy | 328.45 | 7,000 | 2,299,163 | 524,658 | Feb 01 04:19 PM | | DENNER ALEXANDER J | Director | Jan 31 | Buy | 330.52 | 25,800 | 8,527,393 | 517,658 | Feb 01 04:19 PM | | DENNER ALEXANDER J | Director | Jan 30 | Buy | 324.86 | 30,000 | 9,745,851 | 491,858 | Feb 01 04:19 PM | | CAPELLO JEFFREY D | EVP & Chief Financial Officer | Jan 02 | Option Exercise | 0.00 | 1,331 | 0 | 1,331 | Jan 04 04:17 PM | | Guindo Chirfi | EVP Glob. Mkt Acc & Cust Innov | Dec 01 | Option Exercise | 0.00 | 602 | 0 | 2,721 | Dec 04 08:21 PM | | Ehlers Michael D | EVP, Research and Development | Sep 26 | Sale | 350.00 | 1,000 | 350,000 | 4,281 | Sep 27 04:16 PM | | Gregory Ginger | EVP, Human Resources | Aug 01 | Option Exercise | 0.00 | 262 | 0 | 1,122 | Aug 03 04:14 PM |
|
|
|
|
|
|
